Список литературы

Поставить закладку

Dummer R., Heald P.W., Nestle F.O. et al. Sezary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). Blood. 1996; 88 (4): 1383–1389.
Campbell J.J., Clark R.A., Watanabe R., Kupper T.S. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010; 116 (5): 767–771.
da Silva Almeida A.C., Abate F., Khiabanian H. et al. The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome. Nat Genet. 2015; 47 (12): 1465–1470.
Wang L., Ni X., Covington K.R. et al. Genomic proﬁling of Sezary syndrome identiﬁes alterations of key T cell signaling and differentiation genes. Nat Genet. 2015; 47 (12): 1426–1434.
Ungewickell A., Bhaduri A., Rios E. et al. Genomic analysis of mycosis fungoides and Sezary syndrome identiﬁes recurrent alterations in TNFR2. Nat Genet. 2015; 47 (9): 1056–1060.
Berger C.L., Tigelaar R., Cohen J. et al. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood. 2005; 105 (4): 1640–1647.
Spicknall K.E. Sezary syndrome – clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg 2018; 37: 18–23.
Olsen E.A., Rook A.H., Zic J. et al. Sezary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol. 2011; 64 (2): 352–404.
Willemze R., Jaffe E.S., Burg G. et al. WHO-EORTC classiﬁcation for cutaneous lymphomas. Blood. 2005; 105 (10): 3768–3785.
Kubica A.W., Davis M.D., Weaver A.L. et al. Sezary syndrome: a study of 176 patients at Mayo Clinic. J Am Acad Dermatol. 2012; 67 (6): 1189–1199.
Hristov A.C., Tejasvi T., Wilcox R.A. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratiﬁcation, and management. Am J Hematol. 2019; 94: 1027–1041.
Sentis H.J., Willemze R., Scheffer E. Histopathologic studies in Sezary syndrome and erythrodermic mycosis fungoides: a comparison with benign forms of erythroderma. J Am Acad Dermatol. 1986; 15 (6): 1217–1226.
Trotter M.J., Whittaker S.J., Orchard G.E, Smith N.P. Cutaneous histopathology of Sezary syndrome: a study of 41 cases with a proven circulating T-cell clone. J Cutan Pathol. 1997; 24 (5): 286–291.
Klemke C.D., Booken N., Weiss C. et al. Histopathological and immunophenotypical criteria for the diagnosis of Sezary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases. Br J Dermatol. 2015; 173 (1): 93–105.
Diwan A.H., Prieto V.G., Herling M. et al. Primary Sezary syndrome commonly shows low-grade cytologic atypia and an absence of epidermotropism. Am J Clin Pathol. 2005; 123 (4): 510–515.
Morice W.G., Katzmann J.A., Pittelkow M.R. et al. A comparison of morphologic features, ﬂow cytometry, TCR-Vbeta analysis, and TCR-PCR in qualitative and quantitative assessment of peripheral blood involvement by Sezary syndrome. Am J Clin Pathol. 2006; 125 (3): 364–374.
Feng B., Jorgensen J.L., Jones D. et al. Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sezary syndrome using T-cell receptor Vbeta chain antibodies and its application in blood staging. Mod Pathol. 2010; 23 (2): 284–295.
Olsen E., Vonderheid E., Pimpinelli N. et al. Revisions to the staging and classiﬁcation of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007; 110 (6): 1713–1722.
Виноградова Ю.Е., Цыба Н.Н., Гилязитдинова Е.А. и др. Опыт лечения грибовидного микоза и синдрома Сезари в зависимости от стадий заболевания. Результаты собственных исследований и обзор литературы. Клиническая онкогематология 2009; 2 (4): 326–333.
Карамова А.Э., Чикин В.В., Знаменская Л.Ф., Воронцова А.А. Т-клеточные лимфомы кожи: дифференциальная диагностика эритродермических состояний. Вестник дерматологии и венерологии. 2019; 95 (5): 24–32.
Ponti R., Quaglino P., Novelli M. et al. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sezary syndrome) and benign inﬂammatory disease: correlation with clinical, histological and immunophenotypical ﬁndings. Br J Dermatol. 2005; 153 (3): 565–573.
Kirsch I.R., Watanabe R., O’Malley J.T. et al. TCR sequencing facilitates diagnosis and identiﬁes mature T cells as the cell of origin in CTCL. Sci Transl Med. 2015; 7 (308): 308ra158.
Vonderheid E.C. On the diagnosis of erythrodermic cutaneous T-cell lymphoma. J Cutan Pathol. 2006; 33 (Suppl 1): 27–42.
Mann B.S., Johnson J.R, Cohen M.H. et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12 (10): 1247–1252.
Лезвинская Е.М., Вавилов А.М. Лимфопролиферативные опухоли кожи: руководство для врачей. – М.: Практическая медицина, 2010. – 366 с.
Wallace C.A., Sherry D.D. A practical approach to avoidance of methotrexate toxicity [editorial] J Rheumatol. 1995; 22: 1009–1012.
Wood G.S., Wu J. Methotrexate and pralatrexate. Dermatol Clin. 2015; 33 (4): 747–755.
Busger op Vollenbroek F.T., Doggen C.J., Janssens R.W., Bernelot Moens H.J. Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines. PLoS ONE 2018; 13 (3): e0194401.
Ahmadzadeh A., Zamani N., Hassanian-Moghaddam H. et al. Acute versus chronic methotrexate poisoning; a cross-sectional study. BMC Pharmacol Toxicol 2019; 20 (1): 39.
Olsen E.A. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther 2003; 16: 311–321.
Kim Y.H., Tavallaee M., Sundram U. et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: a multi- institution collaborative project. J Clin Oncol. 2015; 33 (32): 3750–3758.
Talpur R., Singh L., Daulat S. et al. Long-term outcomes of 1,263 patients with mycosis fungoidesand Sézary syndrome from 1982 to 2009. Clin Cancer Res. 2012; 18 (18): 5051–5060.
Gobbi P.G., Broglia C., Carnevale Maffe G. et al. Lymphomatous superﬁcial lymph nodes: limitations of physical examination for accurate staging and response assessment. Haematologica. 2002; 87 (11): 1151–1156.
Tsai E.Y., Taur A., Espinosa L. et al. Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol. 2006; 142 (5): 577–584.
Toro J.R., Stoll H.L. Jr, Stomper P.C., Oseroff A.R. Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome. J Am Acad Dermatol 1997; 37 (1): 58–67.
Trautinger F., Eder J., Assaf C. et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome - Update 2017. Eur J Cancer. 2017; 77: 57–74.
Виноградова Ю.Е. Применение интерферона-α при Т-клеточных лимфомах кожи. Гематология и трансфузиология 2012: 57 (3): 99–100.
Zackheim H.S. Epstein E.H. Jr. Low-dose methotrexate for the Sézary syndrome. J Am Acad Dermatol. 1989; 21 (4 Pt 1): 757–762.
Roenigk H.H. Jr, Kuzel T.M., Skoutelis A.P. et al. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol 1990; 95 (6 Suppl); 198S–205S.
Kuzel T.M., Gilyon K., Springer E. et al. Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990; 82 (3); 203–207.
Avilés A., Nambo M.J., Neri N. et al. Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome. Cancer Biother Radiopharm 2007; 22 (6); 836– 840.
Чернова Н.Г., Коломейцев О.А. Современные возможности оптимизации лечения грибовидного микоза и синдрома Сезари. Клиническая онкогематология. 2018;11 (1): 34– 41.
Photiou L., van der Weyden C., McCormack C., Prince H.M. Systemic treatment options for advanced-stage mycosis fungoides and Sézary syndrome. Curr Oncol Rep. 2018; 20 (4):32.
Shiratori S., Fujimoto K., Nishimura M. et al. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome. Hematol Oncol 2016; 34 (1): 9–16.
Wu P.A., Kim Y.H., Lavori P.W. et al. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome. Biol Blood Marrow Transplant 2009; 15 (8): 982–990.
Virmani P., Zain J., Rosen S.T., Hematopoietic stem cell transplantation for mycosis fungoides and Sezary syndrome. Dermatol Clin 2015; 33: 807–818.
Lechowicz M.J., Lazarus H.M., Carreras J. et al. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant 2014; 49 (11): 1360–1365.
Serrano L., Martinez-Escala M.E., Zhou X.A., Guitart J. Pruritus in cutaneous T-cell lymphoma and its management. Dermatol Clin 2018; 36: 245–258.
Schulz S., Metz M., Siepmann D. et al. Antipruritische Wirksamkeit einer hoch dosierten Antihistaminikatherapie. Hautarzt 2009; 60: 564–568.
Weisshaar E., Szepietowski J.C., Dalgard F.J. et al. European S2k guideline on chronic pruritus. Acta Derm Venereol. 2019; 99 (5): 469–506.
Левченко О.К. Опыт оказания противоболевой помощи в гематологическом стационаре. Российский журнал боли. 2019; 17 (1): 47–50.
Абузарова Г.Р., Невзорова Д.В., Кумирова Э.В. и др. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И.Пирогова Минздрава России, Москва, 2016, 94 с.
Абузарова Г.Р. и др. Лечение болевого синдрома у онкологических больных. Российские клинические рекомендации по диагностике и лечению злокачественны лимфопролиферативных заболеваний. Под редакцией И.В Поддубной, В.Г. Савченко, 2018, С.278–288.
Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies. // Am. J. Phys. Med. Rehabil. 2011. Vol. 90, № 5 Suppl 1. P. S88-94.